Genocea Biosciences Stock Forecast for 2023 - 2025 - 2030

Updated on 05/02/2024

Stock Rating
9
Price Target
$0.00
Consensus
-
Upside
0.00%
Analysts
0
Stock Rating
9
Upside
0.00%
Analysts
0
Price Target
$0.00
-

Genocea Biosciences Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Price for Genocea Biosciences has grown by 100.00%, going from $0.00 to $0.00. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach $0.00 – an increase of 100.00%. Over the next six years, experts anticipate that Fair Value growth for Genocea Biosciences will be 100.00%.

2025 Fair Value Forecast
$0.00
2026 Fair Value Forecast
$0.00
2027 Fair Value Forecast
$0.00
2028 Fair Value Forecast
$0.00
2029 Fair Value Forecast
$0.00
2030 Fair Value Forecast
$0.00
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ABBV Stock Forecast AbbVie Outperform 9
$161.72 Buy/Sell $178.42 15.01%
AMGN Stock Forecast Amgen Outperform 4
$277.37 Buy/Sell $303.65 15.19%
GILD Stock Forecast Gilead Sciences Inc Outperform 11
$65.51 Buy/Sell $87.82 22.12%
ALXN Stock Forecast Alexion Pharmaceuticals - 0
$182.50 Buy/Sell $177.38 -100.00%
BIIB Stock Forecast Biogen Outperform 10
$216.13 Buy/Sell $299.62 33.48%

Genocea Biosciences Revenue Forecast for 2023 - 2025 - 2030

In the last year, Revenue for Genocea Biosciences has grown by 20.59%, going from $1.36M to $1.64M. For the following year, the 0 analysts predict that Genocea Biosciences's Revenue will drop by 17.07%, reaching $1.36M. In 2030, the professionals' prediction is that GNCA.Q's Revenue will decrease by 9.97%, reaching $1.48M.

2022 Rev Forecast
$0.00B
2023 Rev Forecast
$0.00B
2024 Rev Forecast
$0.00B
2025 Rev Forecast
$0.00B
2026 Rev Forecast
$0.00B
2027 Rev Forecast
$0.00B
2028 Rev Forecast
$0.00B
2029 Rev Forecast
$0.00B
2030 Rev Forecast
$0.00B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BMRN Stock Forecast BioMarin Pharmaceutical Outperform 10
$83.33 Buy/Sell $111.56 32.01%
INCY Stock Forecast Incyte Outperform 9
$52.94 Buy/Sell $77.05 45.83%
VKTX Stock Forecast Viking Therapeutics Buy 5
$76.43 Buy/Sell $34.00 50.46%

Genocea Biosciences Dividend per Share Forecast for 2023 - 2025 - 2030

Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ARNA Stock Forecast Arena Pharmaceuticals - 6
$99.99 Buy/Sell $100.00 -100.00%
BPMC Stock Forecast Blueprint Medicines Outperform 6
$94.86 Buy/Sell $85.71 5.42%
CCXI Stock Forecast ChemoCentryx - 8
$51.99 Buy/Sell $52.00 -100.00%

Genocea Biosciences Free Cash Flow Forecast for 2023 - 2025 - 2030

Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CBAY Stock Forecast CymaBay Therapeutics - 8
$32.44 Buy/Sell $27.73 -100.00%
IOVA Stock Forecast Iovance Biotherapeutics Buy 4
$12.50 Buy/Sell $20.42 104.00%
DRNA Stock Forecast Dicerna Pharmaceuticals - 7
$38.01 Buy/Sell $35.06 -100.00%

Genocea Biosciences EBITDA Forecast for 2023 - 2025 - 2030

In the last year, Genocea Biosciences's EBITDA has grown, increasing from $-46.45M to $-52.34M – an increase of 12.68%. According to the 0 analysts polled, in the next year, Genocea Biosciences's EBITDA will fall by 11.25%, reaching $-46.45M. By 2030, professionals believe that Genocea Biosciences's EBITDA will have decreased by 6.87%, falling to $-48.75M.

2022 EBITDA Forecast
$-46451750.00
2023 EBITDA Forecast
$-48636530.64
2024 EBITDA Forecast
$-48140438.03
2025 EBITDA Forecast
$-49619954.16
2026 EBITDA Forecast
$-48554779.14
2027 EBITDA Forecast
$-48593622.97
2028 EBITDA Forecast
$-48452701.46
2029 EBITDA Forecast
$-48840323.07
2030 EBITDA Forecast
$-48745898.45
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
FOLD Stock Forecast Amicus Therapeutics Outperform 7
$10.43 Buy/Sell $17.90 91.75%
ARWR Stock Forecast Arrowhead Pharmaceuticals Outperform 7
$23.17 Buy/Sell $52.00 128.74%
ACAD Stock Forecast ACADIA Pharmaceuticals Outperform 6
$17.05 Buy/Sell $33.78 75.07%

Genocea Biosciences EBIT Forecast for 2023 - 2025 - 2030

Genocea Biosciences's EBIT has increased by 13.19% In the last year, going from $-46.99M to $-53.19M. For the next year, 0 analysts project Genocea Biosciences's EBIT to drop by 11.66%, reaching $-46.99M. By 2030, professionals believe that Genocea Biosciences's EBIT will decrease by 7.10%, reaching $-49.42M – a concerning trend for the company.

2022 EBIT Forecast
$-46988046.00
2023 EBIT Forecast
$-49296725.33
2024 EBIT Forecast
$-48780752.94
2025 EBIT Forecast
$-50338484.98
2026 EBIT Forecast
$-49212580.86
2027 EBIT Forecast
$-49255231.77
2028 EBIT Forecast
$-49109107.91
2029 EBIT Forecast
$-49518350.48
2030 EBIT Forecast
$-49416012.56
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CLDX Stock Forecast Celldex Therapeutics Buy 11
$39.35 Buy/Sell $63.29 95.68%
VCEL Stock Forecast Vericel Buy 8
$47.08 Buy/Sell $42.58 16.82%
AGIO Stock Forecast Agios Pharmaceuticals Outperform 9
$33.66 Buy/Sell $40.00 29.23%

Genocea Biosciences EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, EPS for Genocea Biosciences has grown by 100.00%, going from $-0.98 to $0.00. In the coming year, analysts are expecting an increase in EPS, predicting it will reach $0.00 – an increase of 100.00%. Over the next six years, experts anticipate that EPS growth for Genocea Biosciences will be 100.00%.

2025 EPS Forecast
$0.00
2026 EPS Forecast
$0.00
2027 EPS Forecast
$0.00
2028 EPS Forecast
$0.00
2029 EPS Forecast
$0.00
2030 EPS Forecast
$0.00
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ADMA Stock Forecast ADMA Biologics Buy 9
$6.67 Buy/Sell $6.00 19.94%
ARDX Stock Forecast Ardelyx Buy 11
$6.61 Buy/Sell $9.94 104.24%
DVAX Stock Forecast Dynavax Technologies Outperform 11
$11.68 Buy/Sell $25.00 109.76%